Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 17Unknown 12Active not recruiting 7Terminated 4Recruiting 4Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 438Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 176Colorectal Neoplasms 158Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 131Lymphoma 128Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Head and Neck Neoplasms 101Brain Neoplasms 101Recurrence 100Leukemia 97Leukemia, Lymphocytic, Chronic, B-Cell 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 75Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

durvalumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Microsatellite Instability × Clear all
NCT02966587 2018-01-17

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Washington

Phase 2 Withdrawn

Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡